Secondaries announced 12.17.2015
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Iradimed Corporation Symbol: IRMD Price: Last trade $24.68 Trade Date: 12/18 Shares: TBD Underwriter(s) Roth Capital Partners Rating=Subscription Needed